
    
      -  To assess the relative bioavailability of LY03004 compared to Risperdal® Consta® at 25
           mg following multiple intramuscular injections at steady-state;

        -  To evaluate the safety and tolerability of LY03004 following repeated intramuscular
           injections

        -  To evaluate the preliminary efficacy of LY03004 following repeated intramuscular
           injections
    
  